Circulating exosomal miR-34 and miR-122 as promising biomarkers of metabolic dysfunction and insulin resistance in type 2 diabetic patients coexisting with hypothyroidism
Year: 2026
Type: article
Abstract: Type 2 diabetes mellitus (T2DM) and hypothyroidism frequently coexist; however, their combined impact on metabolic and hepatic dysfunction remains incompletely understood. Circulating exosomes and their miRNA cargo have emerged as potential molecular biomarkers reflecting disease associated metabolic alterations. This study aimed to isolate and characterize circulating exosomes and profile exosomal miR-34a and miR-122 in T2DM patients with clinical and subclinical hypothyroidism to evaluate their potential association with insulin resistance, metabolic dysfunction, and hepatic injury related alterations. A total of 143 participants were enrolled: healthy controls (n = 40), T2DM alone (n = 40), T2DM with subclinical hypothyroidism (SC-Hypo, n = 32), and T2DM with clinical hypothyroidism (C-Hypo, n = 31). Exosomes were isolated from serum and characterized by DLS, TEM, and Western blot for exosomal (CD9, CD81). Exosomal miR-34 and miR-122 were quantified by qRT-PCR. Biochemical parameters, insulin resistance markers and thyroid hormones were measured, and ROC analysis evaluated diagnostic performance. Isolated exosomes exhibited typical cup-shaped morphology (100–250 nm) and expressed CD9/CD81. Biochemical parameters (fasting glucose, insulin, TyG Index, HOMA-IR, GGT, AST, ALT, ALP) showed significant stepwise deterioration across groups. Exosomal miR-34 and miR-122 were significantly upregulated in all disease groups, with the highest levels in T2DM + C-Hypo patients. Notably, even SC-Hypo patients showed marked elevation compared to T2DM alone. ROC analysis revealed perfect diagnostic accuracy (AUC = 1.0) with 100% sensitivity and specificity for both miRNAs. Cutoff values for SC-Hypo vs. controls were 1.75 (miR-34) and 1.95 (miR-122); for C-Hypo vs. controls, cutoffs were 1.81 (miR-34) and 2.77 (miR-122). Circulating exosomes and their miRNA cargo—particularly miR-34 and miR-122—are progressively dysregulated in T2DM patients with hypothyroidism. Critically, even subclinical hypothyroidism contributes significantly to this pathological signature, with both miRNAs showing elevation beyond T2DM alone. The perfect diagnostic performance of exosomal miR-34 and miR-122 positions them as leading candidates for early detection and monitoring of metabolic dysfunctions in this high-risk population, highlighting the importance of recognizing subclinical hypothyroidism in T2DM management.
Source: Scientific Reports
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,690
OpenAlex ID: W7230749461
